Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT06028347




Registration number
NCT06028347
Ethics application status
Date submitted
31/08/2023
Date registered
8/09/2023
Date last updated
28/05/2024

Titles & IDs
Public title
Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying mRNA Influenza Vaccine in Healthy Adults
Scientific title
Phase 1, Randomized, Placebo-Controlled, Observer Blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of an Investigational Self-Amplifying mRNA Influenza Vaccine in Healthy Adults
Secondary ID [1] 0 0
V202_01
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Influenza, Human 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - sa-mRNA vaccine Dose 1
Other interventions - sa-mRNA vaccine Dose 2
Other interventions - sa-mRNA vaccine Dose 3
Other interventions - Placebo

Experimental: sa-mRNA vaccine dose 1 -

Experimental: sa-mRNA vaccine dose 2 -

Experimental: sa-mRNA vaccine dose 3 -

Placebo Comparator: Placebo -


Other interventions: sa-mRNA vaccine Dose 1
self-amplifying mRNA vaccine

Other interventions: sa-mRNA vaccine Dose 2
self-amplifying mRNA vaccine

Other interventions: sa-mRNA vaccine Dose 3
self-amplifying mRNA vaccine

Other interventions: Placebo
Saline for injection
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number and percentage of subjects with clinically significant abnormal vital signs and/or acute reactions
Timepoint [1] 0 0
up to 60 minutes or within 6 hours post vaccination
Primary outcome [2] 0 0
Number and percentage of subjects reporting reactogenicity: Solicited local and systemic AEs
Timepoint [2] 0 0
Day 1 to Day 14 of each post vaccination period
Primary outcome [3] 0 0
Number and percentage of subjects reporting unsolicited AEs
Timepoint [3] 0 0
Day 1 to Day 43
Primary outcome [4] 0 0
Number and percentage of subjects reporting AEs leading to study withdrawal, Adverse Events of Special Interest (AESIs), medically attended AEs (MAAEs), and serious adverse events (SAEs).
Timepoint [4] 0 0
Day 1 to Day 202
Primary outcome [5] 0 0
Number and percentage of subjects with Grade 3 or greater abnormal clinically significant hematology and chemistry laboratory values
Timepoint [5] 0 0
Day 3 to Day 43
Primary outcome [6] 0 0
Number and percentage of subjects with grading shifts in hematology and chemistry laboratory assessments
Timepoint [6] 0 0
Day 3 to Day 43
Primary outcome [7] 0 0
Serum antibody titer against the HA glycoprotein in terms of GMT, GMFI, and GMT ratio measured via HI assay
Timepoint [7] 0 0
Day 1, Day 22, Day 43
Primary outcome [8] 0 0
Number and percentage of subjects with HAI titer =1:10 and <1:10 (lower limit of quantification [LLOQ])
Timepoint [8] 0 0
Day 1, Day 22, Day 43
Primary outcome [9] 0 0
Number and percentage of subjects with HAI titer =1:40, =1:80, =1:160 and =1:320
Timepoint [9] 0 0
Day 1, Day 22, Day 43
Primary outcome [10] 0 0
Seroconversion rate (SCR) by HAI assay
Timepoint [10] 0 0
Day 1, Day 22, Day 43
Secondary outcome [1] 0 0
Serum antibody titer against the HA glycoprotein in terms of GMT, GMFI, and GMT ratio measured via HI assay
Timepoint [1] 0 0
Day 1, Day 202
Secondary outcome [2] 0 0
Number and percentage of subjects with =4-fold increase in post-vaccination HAI titer
Timepoint [2] 0 0
Day 1, Day 202
Secondary outcome [3] 0 0
Number and percentage of subjects with HAI titer =1:10 and <1:10 (LLOQ)
Timepoint [3] 0 0
Day 202
Secondary outcome [4] 0 0
Number and percentage of subjects with HAI titer =1:40, =1:80, =1:160 and =1:320
Timepoint [4] 0 0
Day 202
Secondary outcome [5] 0 0
Seroconversion rate (SCR) by HAI assay
Timepoint [5] 0 0
Day 1, Day 202
Secondary outcome [6] 0 0
Serum antibody titer against the NA glycoprotein in terms of GMT, GMFI, and GMT ratio measured via ELLA assay
Timepoint [6] 0 0
Day 1, Day 22, Day 43, Day 202
Secondary outcome [7] 0 0
Number and percentage of subjects with =4-fold increase in post-vaccination ELLA titer
Timepoint [7] 0 0
Day 1, Day 22, Day 43, Day 202

Eligibility
Key inclusion criteria
1. Individuals 18 to 49 years of age OR 65 to 85 years of age, inclusive on the day of
informed consent.

2. Individuals with body mass index (BMI) between 18 and 32 kg/m2, inclusive, at
screening .

3. Individuals who can comply with study procedures including follow-up .
Minimum age
18 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Female participants of childbearing potential who are pregnant, lactating, or who have
not adhered to a specified set of highly effective contraceptive methods from at least
30 days prior to informed consent and who do not plan to do so for the duration of the
study.

2. Male participants who have not adhered to using barrier contraception such as a condom
during at least 60 days after each vaccination, to prevent semen transfer to their
sexual partners and prevent pregnancy of a female partner.

3. Progressive, unstable, or uncontrolled clinical conditions

4. Known hypersensitivity or allergy to any study vaccine component

5. Known history of Guillain-Barré syndrome or other demyelinating disease

6. Condition representing a contraindication to vaccination or blood draw

7. Abnormal function of immune system due to clinical condition, medications, or
radiotherapy.

8. Receipt or planning to receive blood products, non-study vaccine, influenza vaccine,
mRNA-platform vaccine within different timeframes; previous or from study vaccination.

9. Baseline abnormal clinically significant ECG, laboratory safety parameters or vital
signs.

10. Plan to donate blood products (other than for this study), sperm, ova, tissues, or
organs up to 60 days following the last vaccination.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/10/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
24/09/2024
Actual
Sample size
Target
96
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
Nucleus Network Brisbane Clinic - Brisbane
Recruitment hospital [2] 0 0
Nucleus network Melbourne Clinic - Melbourne
Recruitment postcode(s) [1] 0 0
4006 - Brisbane
Recruitment postcode(s) [2] 0 0
3004 - Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Seqirus
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 1, first-in-human, randomized, placebo-controlled, observer blind study. The
effect of two doses of an investigational vaccine on safety, reactogenicity, kinetics and
magnitude of the post-vaccination antibody response will be evaluated at different timepoints
as compared to placebo in healthy adults.

Approximately 96 evaluable subjects will be enrolled in this study; n=72 receiving
investigational vaccine and n=24 receiving placebo.

The study has a screening period (Day -28 to Day -1), a treatment period (Day 1 to Day 43)
and a follow-up period (Day 44 to Day 202).
Trial website
https://clinicaltrials.gov/ct2/show/NCT06028347
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Program Director
Address 0 0
Seqirus
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries